Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx Receives $700K in Funding From Regional Government

NEW YORK (GenomeWeb) — VolitionRx announced today that it has received $700,000 in non-dilutive funding from the government of the Wallonia region of Belgium where the company is headquartered.

According to VolitionRx, roughly $200,000 of the funding is repayable in annual installments over 12 years, beginning in 2020. Additionally, an undisclosed percentage of the company's revenue may be payable to the Walloon regional government over the same period.

VolitionRx said that it intends to use the funds to continue R&D efforts for cancer diagnostics based on its Nucleosomics nucleosome analysis technology.

In late 2017, the firm said that it had received $1.5 million in non-dilutive funding from Sofinex and the Walloon government. It said it has received a total of $3.7 million in non-dilutive funding from local agencies to date.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.